ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SCNI vs CLDI // ENTERPRISE SCALE & MARKET CAP

Scinai Immunotherapeutics Ltd. (NASDAQ) VS. Calidi Biotherapeutics Inc. (NYSE) • 15-METRIC TALLY: SCNI 1 — CLDI 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CLDI
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCNI VS. CLDI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SCNI CLDI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -30.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 99.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 SCNI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 22.7 28.2 -5.58 CLDI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $1.4M $2.5M -$1.1M CLDI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SCNI REV CLDI REV SCNI GROSS % CLDI GROSS % SCNI FCF CLDI FCF
FY 2025 $1.3M $0 -50.0% — -$6.1M -$21.3M
FY 2024 $658.0K $0 -50.0% — -$6.3M -$19.7M
FY 2023 $0 $0 — — -$9.4M -$27.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCNI // BETA —
CLDI // BETA —